An Analysis of Breast Cancer Risk in Women With Single, Multiple, and Atypical Papilloma
Authors:
- Jason T. LewisJLJason T. Lewis
- Lynn C. HartmannLHLynn C. Hartmann
- Robert A. VierkantRVRobert A. Vierkant
- Shaun D. MaloneySMShaun D. Maloney
- V. Shane PankratzVPV. Shane Pankratz
- Teresa M. AllersTATeresa M. Allers
- Marlene H. FrostMFMarlene H. Frost
- Daniel W. VisscherDVDaniel W. Visscher
- 1 June 2006
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 30 (6) , 665-672
Abstract
Breast papillomas may be single or multiple and associated with atypical ductal or lobular hyperplasias (ADH/ALH). The risk of breast carcinoma development in patients with papillomas, particularly those with multiple or atypical lesions, is incompletely defined. Fibrocystic lesions were histopathologically classified in a benign breast disease cohort of 9155 who underwent biopsy from 1967 to 1991, with papilloma assessment in 9108. Individuals with papillomas (N=480) were classified into 4 groups: single papilloma (SP, N=372), single papilloma with ADH or ALH (SP+A, N=54), multiple (>5) papillomas (MP, N=41), and multiple papillomas with ADH or ALH (MP+A, N=13). Those without papillomas were classified as nonproliferative (NP, N=6053), proliferative without atypia (PDWA, N=2308), and ADH/ALH [atypical hyperplasia (AH), N=267]. The relative risk of cancer development within our cohort was compared to that expected in the general population using standardized incidence ratios. The relative risk of breast cancer development associated with SP [2.04, 95% confidence interval (CI) 1.43-2.81] was greater than NP (1.28, 95% CI 1.16-1.42) but similar to PDWA (1.90, 95% CI 1.66-2.16). The risk associated with SP+A (5.11, 95% CI 2.64-8.92) was highly elevated but not substantively different than atypical hyperplasia (4.17, 95% CI 3.10-5.50). Patients with MP are at increased risk compared with PDWA or SP (3.01, 95% CI 1.10-6.55), particularly those with MP+A (7.01, 95% CI 1.91-17.97). There was a marginal increase in breast cancer risk (16%) among patients with proliferative disease if a papilloma was present, but this did not reach statistical significance (P=0.29). The observed frequency of ipsilateral (vs. contralateral) breast cancer development in papilloma subsets was not significantly different than other patient groups. We conclude that SP imparts a cancer risk similar to conventional proliferative fibrocystic change. The presence of papilloma in, or associated with, atypia does not modify the risk connotation of ADH/ALH overall. MP constitutes a proliferative breast disease subset having unique clinical and biologic behavior.Keywords
This publication has 25 references indexed in Scilit:
- Are Solitary Breast Papillomas Entirely Benign?Archives of Surgery, 2003
- Clinicopathologic analysis of breast lesions associated with multiple papillomasHuman Pathology, 2003
- Prognostic significance of benign proliferative breast diseaseCancer, 1993
- Breast cancer risk associated with proliferative breast disease and atypical hyperplasiaCancer, 1993
- Benign papillary neoplasms of the breast: mammographic findings.Radiology, 1991
- A PROSPECTIVE STUDY OF THE DEVELOPMENT OF BREAST CANCER IN 16,692 WOMEN WITH BENIGN BREAST DISEASEAmerican Journal of Epidemiology, 1988
- BREAST CANCER RISK ASSOCIATED WITH PROLIFERATIVE DISEASE, AGE AT FIRST BIRTH, AND A FAMILY HISTORY OF BREAST CANCER1American Journal of Epidemiology, 1987
- Risk Factors for Breast Cancer in Women with Proliferative Breast DiseaseNew England Journal of Medicine, 1985
- Intraductal papillary tumors of the breast.A study of 78 casesCancer, 1977
- THE PAPILLARY NEOPLASMS OF THE BREAST. I. BENIGN INTRADUCTAL PAPILLOMAAnnals of Surgery, 1951